Literature DB >> 31798706

Comparison of urokinase and reteplase thrombolytic treatment in patients with high-risk pulmonary embolism.

Yi Zhang1, Lan Ma2, Qi Fu3, Tao Zhao2, Rui-Ying Yan2, Xing Su2.   

Abstract

Thrombolytic treatment is recommended for patients with high-risk pulmonary embolism. The present study compared thrombolytic therapy with urokinase and reteplase. A total of 37 patients presenting with acute high-risk pulmonary embolism at the Intensive Care Unit of Weinan Central Hospital of Shaanxi Province (Weinan, China) between June 2013 and January 2017 were retrospectively analyzed. According to their treatment, these subjects were assigned to the reteplase group (n=16) or the urokinase group (n=21). Systolic blood pressure (SBP), heart rate (HR) and respiratory rate (RR) were recorded prior to, and at 2, 4, 24 and 48 h after thrombolytic therapy. Complications, including bleeding, were closely monitored. Changes in blood gas analysis, troponin-T (TNT), pro-B-type natriuretic peptide (pro-BNP) and D-dimer (D-D) were observed. In the reteplase and urokinase group, 11 and 13 cases exhibited marked improvement, treatment was rated as effective in 4 and 6 cases, and 1 and 2 mortalities occurred, resulting in an overall effective rate of 93.8 and 90.5%, respectively (P>0.05). In the reteplase group, one patient was unsuccessfully resuscitated and died. In the urokinase group, one patient died of gastric hemorrhage after 22 h of thrombolysis, while another patient died of brain failure resuscitation. The treatment improved the SBP in each of the two groups (P<0.05), and this outcome was similar between these two groups (P>0.05). HR and RR were similar prior to and after thrombolytic therapy (P>0.05). In contrast to the urokinase group, TNT was significantly decreased after thrombolyis compared with the baseline in the reteplase group. Complications in the reteplase group were higher, but in contrast to the urokinase group, no life-threatening bleeding occurred. Although reteplase is as effective as urokinase in treating high-risk pulmonary embolism, reteplase may reduce myocardial damage. Copyright: © Zhang et al.

Entities:  

Keywords:  high-risk pulmonary embolism; reteplase; thrombolytic treatment; troponin T; urokinase

Year:  2019        PMID: 31798706      PMCID: PMC6880444          DOI: 10.3892/etm.2019.8153

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  26 in total

Review 1.  D-dimer: An Overview of Hemostasis and Fibrinolysis, Assays, and Clinical Applications.

Authors:  John D Olson
Journal:  Adv Clin Chem       Date:  2015-02-07       Impact factor: 5.394

Review 2.  Effective diagnosis and treatment of pulmonary embolism: Improving patient outcomes.

Authors:  Guy Meyer
Journal:  Arch Cardiovasc Dis       Date:  2014-07-09       Impact factor: 2.340

3.  The evolution of recombinant thrombolytics: Current status and future directions.

Authors:  Yogender Pal Khasa
Journal:  Bioengineered       Date:  2016-10-03       Impact factor: 3.269

Review 4.  Acute phase treatment of pulmonary embolism.

Authors:  George Chalikias; Stavros Konstantinides
Journal:  Curr Vasc Pharmacol       Date:  2014-05       Impact factor: 2.719

Review 5.  Guidance for the treatment of deep vein thrombosis and pulmonary embolism.

Authors:  Michael B Streiff; Giancarlo Agnelli; Jean M Connors; Mark Crowther; Sabine Eichinger; Renato Lopes; Robert D McBane; Stephan Moll; Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

6.  Outcome of out-of-hospital cardiac arrest after fibrinolysis with reteplase in comparison to the return of spontaneous circulation after cardiac arrest score in a geographic region without emergency coronary intervention.

Authors:  Thomas Luiz; Alexander Wilhelms; Christian Madler; Gregor Pollach; Bernd Haaff; Joachim Grüttner; Tim Viergutz
Journal:  Exp Ther Med       Date:  2017-02-22       Impact factor: 2.447

Review 7.  Novel and emerging therapies: thrombus-targeted fibrinolysis.

Authors:  Giuseppe Lippi; Camilla Mattiuzzi; Emmanuel J Favaloro
Journal:  Semin Thromb Hemost       Date:  2012-10-03       Impact factor: 4.180

Review 8.  Deep vein thrombosis: pathogenesis, diagnosis, and medical management.

Authors:  Jonathan Stone; Patrick Hangge; Hassan Albadawi; Alex Wallace; Fadi Shamoun; M Grace Knuttien; Sailendra Naidu; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

9.  More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.

Authors:  R W Smalling; C Bode; J Kalbfleisch; S Sen; P Limbourg; F Forycki; G Habib; R Feldman; S Hohnloser; A Seals
Journal:  Circulation       Date:  1995-06-01       Impact factor: 29.690

10.  Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).

Authors:  Adam Torbicki; Arnaud Perrier; Stavros Konstantinides; Giancarlo Agnelli; Nazzareno Galiè; Piotr Pruszczyk; Frank Bengel; Adrian J B Brady; Daniel Ferreira; Uwe Janssens; Walter Klepetko; Eckhard Mayer; Martine Remy-Jardin; Jean-Pierre Bassand
Journal:  Eur Heart J       Date:  2008-08-30       Impact factor: 29.983

View more
  2 in total

1.  MicroRNA 449a can Attenuate Protective Effect of Urokinase Against Pulmonary Embolism.

Authors:  Ran Zhu; Wei-Yi Qi; Ting-Wei Liu; Fan Liu
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

2.  Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor.

Authors:  Ran Zhu; Ting-Wei Liu; Fan Liu
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.